Citi lowered the firm’s price target on Acadia Pharmaceuticals (ACAD) to $32 from $33 and keeps a Buy rating on the shares.
Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on ACAD:
- ACADIA Pharmaceuticals Signals Confident Path After Q1 Call
- ACADIA: Buy Rating Reiterated on Durable Commercial Strength and Pipeline Catalysts; $37 Price Target Maintained
- ACADIA: Buy Rating Reiterated on Nuplazid/Daybue Upside and Remlifanserin Optionality; $32 DCF-Based Price Target Maintained
- Acadia Pharmaceuticals reports Q1 EPS 2c, consensus 8c
- Acadia Pharmaceuticals backs FY26 revenue view $1.22B-$1.28B, consensus $1.25B